Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Current Leases: 2019-2024

Historic Current Leases for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $13.5 million.

  • Beam Therapeutics' Current Leases fell 1.92% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year decrease of 1.92%. This contributed to the annual value of $13.5 million for FY2024, which is 5.41% up from last year.
  • Latest data reveals that Beam Therapeutics reported Current Leases of $13.5 million as of FY2024, which was up 5.41% from $12.8 million recorded in FY2023.
  • Over the past 5 years, Beam Therapeutics' Current Leases peaked at $13.5 million during FY2024, and registered a low of $4.2 million during FY2020.
  • Moreover, its 3-year median value for Current Leases was $12.8 million (2023), whereas its average is $12.2 million.
  • As far as peak fluctuations go, Beam Therapeutics' Current Leases fell by 2.74% in 2020, and later soared by 78.76% in 2021.
  • Beam Therapeutics' Current Leases (Yearly) stood at $4.2 million in 2020, then spiked by 78.76% to $7.5 million in 2021, then soared by 37.67% to $10.4 million in 2022, then increased by 23.10% to $12.8 million in 2023, then climbed by 5.41% to $13.5 million in 2024.